RITONAVIR (ritonavir) by Gen Pharmaceuticals is 12. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection (). First approved in 2024.
Drug data last refreshed 13h ago
12.1 Mechanism of Action Ritonavir is an antiretroviral drug [see ] . 12.2 Pharmacodynamics Cardiac Electrophysiology QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once-daily) controlled crossover study in 45 healthy adults, with 10 measurements over 12 hours…
Worked on RITONAVIR at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance